پایان نامه بررسی ارتباط بین سطح پلاسمایی اندوتلین-1 و پلی‌مورفیسم ژن آن با فشار خون بالا و گرفتگی عروق کرونر

منابع انگلیسی

1. Bagnato A, Rosanò L. The endothelin axis in cancer. The international journal of biochemistry & cell biology. 2008;40(8):1443-51.
2. Nussdorfer GG, Rossi GP, Malendowicz LK, Mazzocchi G. Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacological reviews. 1999;51(3):403-38.
3. Masaki T. Historical review: endothelin. Trends in pharmacological sciences. 2004;25(4):219-24.
4. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102(19):2434-40.
5. Khimji A-k, Rockey DC. Endothelin—biology and disease. Cellular signalling. 2010;22(11):1615-25.
6. Schiffrin E. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995;25(6):1135-43.
7. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nature Reviews Cancer. 2003;3(2):110-6.
8. Masaki T. The endothelin family: an overview. J Cardiovasc Pharmacol. [10.1097/00005344-200000002-00002]. 2000 //;35:S3-S5.
9. Vignon-Zellweger N, Heiden S, Miyauchi T, Emoto N. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci. 2012 Oct 15;91(13-14):490-500.
10. Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vascular health and risk management. 2007;3(1):11.
11. Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovascular research. 2007;76(1):8-18.
12. Liu H, Peng Y, Liu F, Liu Y, Ouyang L, Xiao W, et al. Correlation between endothelin-1 and atherosclerosis in chronic hemodialysis patients. JN journal of nephrology. 2010;23(5):593.
13. Goch A, Banach M, Mikhailidis DP, Rysz J, Henryk Goch J. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clinical and experimental hypertension. 2009;31(1):20-30.
14. Hollegaard MV, Grove J, Thorsen P, Wang X, Mandrup S, Christiansen M, et al. Polymorphisms in the tumor necrosis factor alpha and interleukin 1-beta promoters with possible gene regulatory functions increase the risk of preterm birth. Acta obstetricia et gynecologica Scandinavica. 2008;87(12):1285-90.
15. Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies. Canadian journal of physiology and pharmacology. 2003;81(6):578-87.
16. Piranfar MA. The Correlation between high-sensitivity C-reactive protein (hsCRP) serum levels and severity of coronary atherosclerosis. International cardiovascular research journal. 2014;8(1):6.
17. Syvanen A-C, Landegren U, Isaksson A, Gyllensten U, Brookes A. Enthusiasm mixed with skepticism about singlenucleotide polymorphism markers for dissecting complex disorders. Eur J Hum Genet. 1999;7:98-101.
18. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Annals of internal medicine. 1991;114(6):464-9.
19. Parrinello G, Scaglione R, Pinto A, Corrao S, Cecala M, Di Silvestre G, et al. Central obesity and hypertension The role of plasma endothelin. American journal of hypertension. 1996;9(12):1186-91.
20. Panoulas VF, Douglas KM, Smith JP, Taffe P, Stavropoulos-Kalinoglou A, Toms TE, et al. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium. 2008 Jul-Aug;15(4):203-12.
21. Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, et al. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes. 1995;44(4):431-6.
22. Esteghamati A, Abbasi M, Alikhani S, Gouya MM, Delavari A, Shishehbor MH, et al. Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. American journal of hypertension. 2008;21(6):620-6.
23. Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development? The Journal of Clinical Endocrinology & Metabolism. 2007;92(2):379-85.
24. Giaid A, Yanagisawa M, Langleben D, Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in pulmonary hypertension. The New England journal of medicine. 1993;1993(329):1967-8.
25. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282-6.
26. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991;84(6):2280-5.
27. Iglarz M, Schiffrin EL. Role of endothelin-1 in hypertension. Current hypertension reports. 2003;5(2):144-8.
28. Diefenbach K, Nahad FA, Meisel C, Fietze I, Cascorbi I, Stangl K, et al. Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. Clinical chemistry. 2004;50(2):448-51.
29. Lerman A, Holmes DR, Bell MR, Garratt KN, Nishimura RA, Burnett JC. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92(9):2426-31.
30. Lerman A, Webster M, Chesebro JH, Edwards WD, Wei CM, Fuster V, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88(6):2923-8.
31. Zeiher AM, Goebel H, Schächinger V, Ihling C. Tissue Endothelin-1 Immunoreactivity in the Active Coronary Atherosclerotic Plaque A Clue to the Mechanism of Increased Vasoreactivity of the Culprit Lesion in Unstable Angina. Circulation. 1995;91(4):941-7.
32. Jesmin S, Zaedi S, Maeda S, Togashi H, Yamaguchi I, Goto K, et al. Endothelin antagonism suppresses plasma and cardiac endothelin-1 levels in SHRSPs at the typical hypertensive stage. Experimental Biology and Medicine. 2006;231(6):919-24.
33. McCarter SD, Lai PF, Suen RS, Stewart DJ. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Experimental Biology and Medicine. 2006;231(6):985-91.
34. Pernow J, Shemyakin A, Böhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life sciences. 2012;91(13):507-16.
35. Sayama H, Nakamura Y, Saito N, Konoshita M. Does the plasma endothelin-1 concentration reflect atherosclerosis in the elderly? Gerontology. 1999;45(6):312-6.
36. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation. 2001;104(8):864-9.
37. Noshad H, Argani H, Nezami N, Ghojazadeh M, Zomorrodi A, Bohlouli A, et al. Arterial atherosclerosis in patients with chronic kidney disease and its relationship with serum and tissue. Iranian journal of kidney diseases. 2009;3(4):203-9.
38. Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJ, et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension. 1999;33(5):1169-74.
39. Treiber FA, Barbeau P, Harshfield G, Kang H-S, Pollock DM, Pollock JS, et al. Endothelin-1 gene Lys198Asn polymorphism and blood pressure reactivity. Hypertension. 2003;42(4):494-9.
40. Calabro P, Limongelli G, Maddaloni V, Vizza CD, D’Alto M, D’Alessandro R, et al. Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. Internal and emergency medicine. 2012;7(5):425-30.
41. Dzholdasbekova A, Gaipov A. The association between polymorphism of Lys198Asn of endothelin-1 gene and arterial hypertension risk in Kazakh people. European Journal of General Medicine. 2010;7(2).
42. Seremak-Mrozikiewicz A, Barlik M, Perlik M, Kurzawińska G, Drews K. [Genetic variability of endothelin-1 system in gestational hypertension and preeclampsia]. Ginekologia polska. 2011;82(5):363-70.
43. Vadapalli S, Rani HS, Sastry B, Nallari P. Endothelin-1 and endothelial nitric oxide polymorphisms in idiopathic pulmonary arterial hypertension. Int J Mol Epidemiol Genet. 2010;1(3):208-13.
44. Vasku A, Holla LI, Tschplova S, Muzik J, Soucek M, Vacha J. An association of three polymorphisms in the gene coding for endothelin-1 (ET-1) in essential hypertension. Atherosclerosis. 2000;151(1):255.
45. Ibrahim E, Kassem A, Zakaria N. The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians. Egyptian Journal of Chest Diseases and Tuberculosis. 2012;61(4):495-500.
46. Lajemi M, Gautier S, Poirier O, Baguet J-P, Mimran A, Gosse P, et al. Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives. American journal of hypertension. 2001;14(8):755-60.
47. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids research. 1988;16(3):1215.
48. Katona E, Settakis G, Varga Z, Paragh G, Bereczki D, Fulesdi B, et al. Target-organ damage in adolescent hypertension. Analysis of potential influencing factors, especially nitric oxide and endothelin-1. J Neurol Sci. 2006 Sep 25;247(2):138-43.
49. Rapoport RM. Nitric oxide inhibition of endothelin-1 release in the vasculature: in vivo relevance of in vitro findings. Hypertension. 2014 Nov;64(5):908-14.
50. Wu Y, Duan S, Qiang X, Ning Z, Xing C, Zhang B. Sympathetic renal denervation in hypertension with chronic kidney disease: a case report and review of literature. Int J Clin Exp Med. 2015;8(9):16858-62.
51. Kawashima S. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. Journal of pharmacological sciences. 2004 Dec;96(4):411-9.